Elsevier

Clinical Therapeutics

Volume 30, Issue 10, October 2008, Pages 1747-1765
Clinical Therapeutics

Raltegravir: The first HIV integrase inhibitor

https://doi.org/10.1016/j.clinthera.2008.10.012Get rights and content

Abstract

Background: The availability of new classes of antiretroviral drugs has made it possible for HIV-infected individuals who are highly treatment experienced to achieve the goals of immunologic recovery and virologic suppression. Raltegravir is the first integrase inhibitor to be approved by the US Food and Drug Administration for use in antiretroviral treatment- experienced adult patients with viral resistance.

Objective: This article reviews the pharmacology, pharmacokinetics, pharmacodynamics, efficacy, tolerability, resistance profile, drug interactions, and dosing and administration of raltegravir.

Methods: Searches of MEDLINE and International Pharmaceutical Abstracts from 1964 to July 2008 were conducted using the terms integrase, raltegravir, and MK-0518. Relevant information was extracted from the identified clinical trials and review articles. Abstracts from the Conference on Retroviruses and Opportunistic Infections (1998-2008); Interscience Conference on Antimicrobial Agents and Chemotherapy (1999-2007); International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (2001-2007); and European AIDS Conference (2001-2007) were also searched.

Results: Raltegravir blocks HIV replication by inhibiting essential strand-transfer activities of integrase. Raltegravir is rapidly absorbed, with a median Tmax of ~4 hours in the fasting state. No dose adjustment is recommended in patients with moderate renal or hepatic insufficiency, and raltegravir may be taken without regard to meals. In Phase II studies in treatment-naive patients, raltegravir had efficacy similar to that of standard initial therapies. In 2 interrelated Phase III clinical studies in treatment-experienced patients with drug-resistant disease, the addition of raltegravir to an optimized background regimen significantly lowered HIV RNA compared with optimized background treatment alone (62.1% vs 32.9%, respectively; P < 0.001). Raltegravir was generally well tolerated. The most common adverse effects reported in Phase II/III trials in treatment-experienced patients were diarrhea (16.6%), nausea (9.9%), and headache (9.7%). Cytochrome P450–related drug interactions are not expected, as raltegravir is not a CYP substrate, inducer, or inhibitor. However, to prevent failure of raltegravir, the drug should not be coadministered with rifampin.

Conclusion: Raltegravir is a potent and generally well tolerated antiretroviral agent that may play an important role in the treatment of patients harboring resistance to other antiretrovirals.

References (49)

  • RT Steigbigel et al.

    Raltegravir with optimized background therapy for resistant HIV-1 infection

    N Engl J Med.

    (2008)
  • HIV/AIDS Surveillance...
  • US Food and Drug Administration. Drugs used in the treatment of HIV...
  • B Van Maele et al.

    HIV-1 integration: An interplay between HIV-1 integrase, cellular and viral proteins

    AIDS Rev.

    (2005)
  • M Lataillade et al.

    The hunt for HIV-1 integrase inhibitors

    AIDS Patient Care STDS.

    (2006)
  • DJ Hazuda et al.

    Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

    Science.

    (2000)
  • V Summa et al.

    Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection

    J Med Chem.

    (2008)
  • Summa V, Pace P, Petrocchi A, et al. Discovery of MK-0518 a novel, potent and selective HIV integrase inhibitor in...
  • Isentress [package...
  • Raltegravir [scientific...
  • Scientific discussion of raltegravir. Annex I: Summary of product...
  • Wenning L, Nguyen B, Teppler H. Pharmacokinetic/pharmacodynamic (PK/PD) analyses for raltegravir (RAL) in phase II and...
  • M Iwamoto et al.

    Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects

    Clin Pharmacol Ther.

    (2008)
  • Petry AS, Wenning LA, Laetham M, et al. Safety, tolerability, and pharmacokinetics after single and multiple doses of...
  • M Markowitz et al.

    Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals

    J Acquir Immune Defic Syndr.

    (2006)
  • Wenning L, Anderson M, Petry A, et al. Raltegravir (RAL) dose proportionality and effect of food. Presented at: 47th...
  • Petry AS, Hanley WD, Silk G, et al. Effect of severe renal insufficiency on raltegravir (RAL) pharmacokinetics....
  • K Kassahun et al.

    Metabolism and disposition in humans of raltegravir (MK-0518), an anti- AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme

    Drug Metab Dispos.

    (2007)
  • Miller M, Witmer M, Stillmock K, et al. Biochemical and antiviral activity of MK-0518, a potent HIV integrase...
  • Arponen S, Benito J, Lozano S, et al. More pronounced effect of integrase inhibitor raltegravir on proviral DNA...
  • JM Murray et al.

    Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

    AIDS.

    (2007)
  • M Markowitz et al.

    Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled study

    J Acquir Immune Defic Syndr.

    (2007)
  • B Grinsztejn et al.

    Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial

    Lancet.

    (2007)
  • Grinsztejn B, Nguyen B, Katlama C, et al. 48 Week efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in...
  • Cited by (109)

    • HIV integrase inhibitors that inhibit strand transfer interact with RAG1 and hamper its activities

      2021, International Immunopharmacology
      Citation Excerpt :

      It was the first HIV integrase inhibitor to be approved and was sold under the brand name Isentress®. It belongs to diketo acid class of inhibitors and was seen to be metabolized through glucuronidation [24]. Sato and co-workers in 2006 showed that 4-quinolone-3-carboxylic acids are an alternative to diketo acids, leading to the discovery of Elvitegravir (GS-9137) (Fig. 3), which could efficiently inhibit HIV-1 integrase [25].

    View all citing articles on Scopus
    View full text